DK0769949T3 - Hydromorphonterapi - Google Patents

Hydromorphonterapi

Info

Publication number
DK0769949T3
DK0769949T3 DK95924665T DK95924665T DK0769949T3 DK 0769949 T3 DK0769949 T3 DK 0769949T3 DK 95924665 T DK95924665 T DK 95924665T DK 95924665 T DK95924665 T DK 95924665T DK 0769949 T3 DK0769949 T3 DK 0769949T3
Authority
DK
Denmark
Prior art keywords
hydromorphone
oral
composition
therapy
hydromorphone therapy
Prior art date
Application number
DK95924665T
Other languages
English (en)
Inventor
Sonya Merril
Atul D Ayer
Navjot Chadha
Anthony L Kuczynski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK0769949T3 publication Critical patent/DK0769949T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Electronic Switches (AREA)
DK95924665T 1994-07-07 1995-06-23 Hydromorphonterapi DK0769949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/271,593 US5529787A (en) 1994-07-07 1994-07-07 Hydromorphone therapy
PCT/US1995/007950 WO1996001629A1 (en) 1994-07-07 1995-06-23 Hydromorphone therapy

Publications (1)

Publication Number Publication Date
DK0769949T3 true DK0769949T3 (da) 2003-02-24

Family

ID=23036244

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95924665T DK0769949T3 (da) 1994-07-07 1995-06-23 Hydromorphonterapi
DK99204122T DK1025845T3 (da) 1994-07-07 1995-06-23 Hydromorfonterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99204122T DK1025845T3 (da) 1994-07-07 1995-06-23 Hydromorfonterapi

Country Status (12)

Country Link
US (2) US5529787A (da)
EP (2) EP1025845B1 (da)
AT (2) ATE227575T1 (da)
AU (1) AU693910B2 (da)
CA (1) CA2188451A1 (da)
DE (2) DE69528852T2 (da)
DK (2) DK0769949T3 (da)
ES (2) ES2186302T3 (da)
NZ (1) NZ289289A (da)
PT (1) PT1025845E (da)
WO (1) WO1996001629A1 (da)
ZA (1) ZA955674B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
DE69730027T2 (de) * 1996-05-24 2004-11-25 Alza Corp., Mountain View Abgabevorrichtung zur Abgabe eines Farbstoffs an eine Nähstoffformulie- rung
US6190351B1 (en) * 1997-02-28 2001-02-20 Alza Corporation Nutritional support system
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001037815A1 (en) * 1999-11-22 2001-05-31 Alza Corporation Osmotic dosage form comprising first and second
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
AU783685B2 (en) * 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1315533A4 (en) * 2000-08-15 2007-06-27 Univ Kentucky Res Found PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DK1551372T3 (da) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sekvestreringsunderenhed og relaterede sammensætninger og fremgangsmåder
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
WO2005030166A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
US8246986B2 (en) * 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
CA2540056C (en) * 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US8044112B2 (en) * 2006-03-30 2011-10-25 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
HUE027342T2 (en) * 2006-10-30 2016-09-28 Novartis Ag Method for applying a hydrophilic coating to a contact lens of silicone hydrogel
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20090076135A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched hydromorphone
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy

Also Published As

Publication number Publication date
US5529787A (en) 1996-06-25
PT1025845E (pt) 2003-03-31
ES2186724T3 (es) 2003-05-16
CA2188451A1 (en) 1996-01-25
DE69528852D1 (de) 2002-12-19
AU2908395A (en) 1996-02-09
EP0769949B1 (en) 2003-01-15
AU693910B2 (en) 1998-07-09
WO1996001629A1 (en) 1996-01-25
ZA955674B (en) 1996-02-20
ATE227575T1 (de) 2002-11-15
DE69529412D1 (en) 2003-02-20
DE69529412T2 (de) 2003-07-31
EP1025845A2 (en) 2000-08-09
EP1025845B1 (en) 2002-11-13
EP0769949A1 (en) 1997-05-02
ES2186302T3 (es) 2003-05-01
ATE230992T1 (de) 2003-02-15
DE69528852T2 (de) 2003-09-18
US5702725A (en) 1997-12-30
DK1025845T3 (da) 2002-12-30
NZ289289A (en) 1997-10-24
EP1025845A3 (en) 2000-12-13

Similar Documents

Publication Publication Date Title
ATE230992T1 (de) Hydromorphone-therapie
EP1478406A4 (en) COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
DK0998287T3 (da) Anvendelse af levobupivacain
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
IL159766A0 (en) A sustained release oral dosage form of a hydromorphone
MY112915A (en) Multiple unit tableted dosage form 1
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
SE9504661D0 (sv) New compounds
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
GB9818916D0 (en) Use
FR2710915B1 (fr) Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
IT1285770B1 (it) Composti corticoidei
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
SI0770384T1 (en) Solid, anhydrous, pharmaceutical compositions for vaginal use
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
GB9420747D0 (en) 1,5 benzodiazepine derivatives
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
GR3026551T3 (en) Composition of polymers for medical applications.
HU9501654D0 (en) Tablet, capsule, or granule comprising desogestrel
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
BG104692A (en) Extended release tiagabine formulation
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide